Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL

被引：5

作者：

Trahair, T. N. ^{[1
,2
,3
]}

Lock, R. B. ^{[2
,3
]}

Sutton, R. ^{[2
,3
]}

Sia, K. C. S. ^{[2
,3
]}

Evans, K. ^{[2
]}

Richmond, J. ^{[2
]}

Law, T. ^{[2
]}

Venn, N. C. ^{[2
]}

Irving, J. A. ^{[4
]}

Moore, S. ^{[5
]}

Nievergall, E. ^{[6
,7
]}

Dang, P. ^{[6
]}

Heatley, S. L. ^{[6
,7
]}

White, D. L. ^{[6
,7
,8
]}

Revesz, T. ^{[8
,9
]}

机构：

[1] Sydney Childrens Hosp, Kids Canc Ctr, High St, Randwick, NSW, Australia

[2] UNSW Australia, Lowy Canc Res Ctr, Childrens Canc Inst, Sydney, NSW, Australia

[3] UNSW Australia, Sch Womens & Childrens Hlth, Sydney, NSW, Australia

[4] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England

[5] SA Pathol, Dept Genet Pathol, Adelaide, SA, Australia

[6] SAHMRI, Adelaide, SA, Australia

[7] Univ Adelaide, Discipline Med, Adelaide, SA, Australia

[8] Univ Adelaide, Discipline Paediat, Adelaide, SA, Australia

[9] Womens & Childrens Hosp, SA Pathol, Adelaide, SA, Australia

来源：

BONE MARROW TRANSPLANTATION | 2016年 / 51卷 / 09期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; PRECLINICAL TESTING PROGRAM; 1ST RELAPSE; BORTEZOMIB; TOPOTECAN; MODELS;

D O I：

10.1038/bmt.2016.122

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：1279 / 1282

页数：4

共 15 条

[1] Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group [J].

Bader, Peter ;

Kreyenberg, Hermann ;

Henze, Guenter H. R. ;

Eckert, Cornelia ;

Reising, Miriam ;

Willasch, Andre ;

Barth, Andrea ;

Borkhardt, Arndt ;

Peters, Christina ;

Handgretinger, Rupert ;

Sykora, Karl-Walter ;

Holter, Wolfgang ;

Kabisch, Hartmut ;

Klingebiel, Thomas ;

von Stackelberg, Arend .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :377-384

[2] The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia [J].

Carol, Hernan ;

Szymanska, Barbara ;

Evans, Kathryn ;

Boehm, Ingrid ;

Houghton, Peter J. ;

Smith, Malcolm A. ;

Lock, Richard B. .

CLINICAL CANCER RESEARCH, 2013, 19 (07) :1795-1805

[3] Initial Testing of Topotecan by the Pediatric Preclinical Testing Program [J].

Carol, Hernan ;

Houghton, Peter J. ;

Morton, Christopher L. ;

Kolb, E. Anders ;

Gorlick, Richard ;

Reynolds, C. Patrick ;

Kang, Min H. ;

Maris, John M. ;

Keir, Stephen T. ;

Watkins, Amy ;

Smith, Malcolm A. ;

Lock, Richard B. .

PEDIATRIC BLOOD & CANCER, 2010, 54 (05) :707-715

[4] Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia [J].

Case, Marian ;

Matheson, Elizabeth ;

Minto, Lynne ;

Hassan, Rosline ;

Harrison, Christine J. ;

Bown, Nick ;

Bailey, Simon ;

Vormoor, Josef ;

Hall, Andrew G. ;

Irving, Julie A. E. .

CANCER RESEARCH, 2008, 68 (16) :6803-6809

[5] Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse [J].

Clappier, Emmanuelle ;

Gerby, Bastien ;

Sigaux, Francois ;

Delord, Marc ;

Touzri, Farah ;

Hernandez, Lucie ;

Ballerini, Paola ;

Baruchel, Andre ;

Pflumio, Francoise ;

Soulier, Jean .

JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (04) :653-661

[6] Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant [J].

Eapen, M ;

Giralt, SA ;

Horowitz, MM ;

Klein, JP ;

Wagner, JE ;

Zhang, MJ ;

Tallman, MS ;

Marks, DI ;

Camitta, BM ;

Champlin, RE ;

Ringdén, O ;

Bredeson, CN ;

Martino, R ;

Gale, RP ;

Cairo, MS ;

Litzow, MR ;

deLima, M .

BONE MARROW TRANSPLANTATION, 2004, 34 (08) :721-727

[7] Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse [J].

Hijiya, Nobuko ;

Stewart, Clinton F. ;

Zhou, Yinmei ;

Campana, Dario ;

Coustan-Smith, Elaine ;

Rivera, Gaston K. ;

Relling, Mary V. ;

Pui, Ching-Hon ;

Gajjar, Arnar .

CANCER, 2008, 112 (09) :1983-1991

[8] Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program [J].

Houghton, Peter J. ;

Morton, Christopher L. ;

Kolb, E. Anders ;

Lock, Richard ;

Carol, Hernan ;

Reynolds, C. Patrick ;

Keshelava, Nino ;

Maris, John M. ;

Keir, Stephen T. ;

Wu, Jianrong ;

Smith, Malcolm A. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (01) :37-45

[9] Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies [J].

Liem, NLM ;

Papa, RA ;

Milross, CG ;

Schmid, MA ;

Tajbakhsh, M ;

Choi, S ;

Ramirez, CD ;

Rice, AM ;

Haber, M ;

Norris, MD ;

MacKenzie, KL ;

Lock, RB .

BLOOD, 2004, 103 (10) :3905-3914

[10] Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study [J].

Messinger, Yoav H. ;

Gaynon, Paul S. ;

Sposto, Richard ;

van der Giessen, Jeannette ;

Eckroth, Elena ;

Malvar, Jemily ;

Bostrom, Bruce C. .

BLOOD, 2012, 120 (02) :285-290

← 1 2 →